Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

por Manitz, Juliane, D'Angelo, Sandra P, Apolo, Andrea B, Eggleton, S Peter, Bajars, Marcis, Bohnsack, Oliver, Gulley, James L
Publicado 2022

Efficacy and immune-related adverse event associations in avelumab-treated patients

por Kelly, Karen, Manitz, Juliane, Patel, Manish R, D’Angelo, Sandra P, Apolo, Andrea B, Rajan, Arun, Kasturi, Vijay, Speit, Isabell, Bajars, Marcis, Warth, John, Gulley, James L
Publicado 2020

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

por Vaishampayan, Ulka, Schöffski, Patrick, Ravaud, Alain, Borel, Christian, Peguero, Julio, Chaves, Jorge, Morris, John C., Kotecki, Nuria, Smakal, Martin, Zhou, Dongli, Guenther, Silke, Bajars, Marcis, Gulley, James L.
Publicado 2019

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

por Hrinczenko, Borys, Iannotti, Nicholas, Goel, Sanjay, Spigel, David, Safran, Howard, Taylor, Matthew H, Bennouna, Jaafar, Wong, Deborah J, Kelly, Karen, Verschraegen, Claire, Bajars, Marcis, Manitz, Juliane, Ruisi, Mary, Gulley, James L
Publicado 2022

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

por Guigay, Joël, Lee, Keun-Wook, Patel, Manish R, Daste, Amaury, Wong, Deborah J, Goel, Sanjay, Gordon, Michael S, Gutierrez, Martin, Balmanoukian, Ani, Le Tourneau, Christophe, Mita, Alain, Vansteene, Damien, Keilholz, Ulrich, Schöffski, Patrick, Grote, Hans Juergen, Zhou, Dongli, Bajars, Marcis, Penel, Nicolas
Publicado 2021

Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

por D'Angelo, Sandra P, Bhatia, Shailender, Brohl, Andrew S, Hamid, Omid, Mehnert, Janice M, Terheyden, Patrick, Shih, Kent C, Brownell, Isaac, Lebbé, Celeste, Lewis, Karl D, Linette, Gerald P, Milella, Michele, Georges, Sara, Shah, Parantu, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul T
Publicado 2020

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

por Verschraegen, Claire F, Jerusalem, Guy, McClay, Edward F, Iannotti, Nicholas, Redfern, Charles H, Bennouna, Jaafar, Chen, Franklin L, Kelly, Karen, Mehnert, Janice, Morris, John C, Taylor, Matthew, Spigel, David, Wang, Ding, Grote, Hans Juergen, Zhou, Dongli, Munshi, Neru, Bajars, Marcis, Gulley, James L
Publicado 2020

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab

por Bharmal, Murtuza, Nolte, Sandra, Lebbé, Céleste, Mortier, Laurent, Brohl, Andrew S, Fazio, Nicola, Grob, Jean-Jacquez, Pusceddu, Sara, Hanna, Glenn J, Hassel, Jessica C, Kiecker, Felix, Ellers-Lenz, Barbara, Bajars, Marcis, Güzel, Gülseren, Nghiem, Paul, Hunger, Matthias, Schlichting, Michael, Henry-Szatkowski, Mickaël, D'Angelo, Sandra P
Publicado 2020

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

por Yoo, Changhoon, Javle, Milind M., Verdaguer Mata, Helena, de Braud, Filippo, Trojan, Jörg, Raoul, Jean-Luc, Kim, Jin Won, Ueno, Makoto, Lee, Choong-kun, Hijioka, Susumu, Cubillo, Antonio, Furuse, Junji, Azad, Nilofer, Sato, Masashi, Vugmeyster, Yulia, Machl, Andreas, Bajars, Marcis, Bridgewater, John, Oh, Do-Youn, Borad, Mitesh J.
Publicado 2023